Immunovant, Inc. (IMVT) › Operating Cash FlowImmunovant, Inc. (IMVT) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: -$28.55M2020: -$53.36M2021: -$83.33M2022: -$106.11M2023: -$188.19M2024: -$214.23M2025: -$375.87M2026: -$407.31M-$407.31M2019Operating Cash Flow (USD)2026Fiscal YearOperating Cash FlowChange YoY2026-$407.31M-8.4%2025-$375.87M-75.5%2024-$214.23M-13.8%2023-$188.19M-77.4%2022-$106.11M-27.3%2021-$83.33M-56.2%2020-$53.36M-86.9%2019-$28.55M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share